We are live on !
Find out more
Enavate Sciences Portfolio holdings
AUM
$345M
Turnover
0%
1-Year Est. Return
134.64%
This Quarter Est. Return
-27.33%
1 Year Est. Return
+134.64%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$133M
AUM Growth
-$6.52M
(-4.7%)
Cap. Flow
+$52.9M
Cap. Flow % of AUM
Cap. Flow %
39.84%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
1
Reduced
–
Closed
–
Avg Time Held
0.2
years
Top 10 Avg Time Held
0.2
years
Top 20 Avg Time Held
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sionna Therapeutics
SION
|
+$40.5M |
| 2 |
Immunome
IMNM
|
+$12.4M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Immunome
IMNM
$2.21B
| $32.1M | 24.18% |
4,768,583
+1,290,322
| +37% | +$12.4M |
2024 Q4
1 quarter
|
|
2
Zenas BioPharma
ZBIO
$1.82B
| $29.7M | 22.39% |
3,761,359
| – | – |
2024 Q4
1 quarter
|
|
|
3
Sionna Therapeutics
SION
$146M
| $25.9M | 19.53% |
+2,478,030
| New | +$40.5M |
2025 Q1
0 quarters
|
|
4
CAMP4 Therapeutics
CAMP
$242M
| $15.1M | 11.41% |
3,785,802
| – | – |
2024 Q4
1 quarter
|
|
5
Upstream Bio Inc
UPB
$171M
| $15.1M | 11.34% |
2,459,703
| – | – |
2024 Q4
1 quarter
|
|
6
Compass Therapeutics
CMPX
$127M
| $14.8M | 11.15% |
7,788,150
| – | – |
2024 Q4
1 quarter
|
|
Similar funds
LCM
WFI
Enavate Sciences's Q1 2025 Portfolio in Review
As of Q1 2025, Enavate Sciences held 6 positions worth $133M, down 4.7% from $139M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Enavate Sciences deployed $52.9M of net new capital in Q1 2025, opening 1 new position and adding to 1 existing holding. Its largest new stake was Sionna Therapeutics: 2,478,030 shares worth $25.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Enavate Sciences's largest Q1 2025 buy was Sionna Therapeutics: 2,478,030 shares worth $25.9M.
- Enavate Sciences added most to Immunome in Q1 2025, an estimated $12.4M increase.
- Enavate Sciences's ten largest holdings make up 100% of its $133M portfolio in Q1 2025.
- Enavate Sciences opened 1 new position and closed 0 in Q1 2025.
- Enavate Sciences's portfolio value fell 4.7% quarter-over-quarter to $133M.
Based on Enavate Sciences's 13F filing for Q1 2025, filed 15 May 2025.